Serial 18F-fluorodeoxyglucose positron emission tomography to assess the efficacy of infliximab in steroid refractory cardiac sarcoidosis
Graphical abstract summarizing the findings of this observational study, which through serial 18 F-FDG-PET/CT imaging, supports the use of infliximab in the management of refractory cardiac sarcoidosis . CMA - cardiac metabolic activity, EF - ejection fraction, 18 F-FDG-PET/CT - fluorodeoxyglucose-positron emission tomography/computed tomography, LV - left ventricular, MRI - magnetic resonance imaging, SUV - standardized uptake value
Authors
- Khalid Hussain (ORCID: https://orcid.org/0000-0002-3714-8696)
- A. Dushani C. U. Ranasinghe (ORCID: https://orcid.org/0000-0002-1569-6886)
- Emma Jenkins (ORCID: https://orcid.org/0000-0001-5860-8762)
- Tamara Naneishvili (ORCID: https://orcid.org/0000-0001-9577-7186)
- Francisco Leyva‐Leon
- Louise Crowley (ORCID: https://orcid.org/0000-0001-6261-5041)
- William E. Moody (ORCID: https://orcid.org/0000-0002-2592-618X)
- Anjali Crawshaw (ORCID: https://orcid.org/0000-0001-7304-6374)
- Mengshi Yuan
Institutions
- University Hospitals Birmingham NHS Foundation Trust (GB)
Publication Details
- Journal
- Journal of Nuclear Cardiology
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1016/j.nuclcard.2025.102265
- Citations
- 1
- Primary Topic
- Sarcoidosis and Beryllium Toxicity Research
- Type
- article
- Field-Weighted Citation Impact
- 1.16